CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 89 enrolled
Drug / intervention
lanreotide (Autogel formulation)drug
Likely dose
lanreotide (Autogel formulation) 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00842348
NCT00842348Phase 3Completed
CompareCT.gov

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Ipsen·interventional·Posted Feb 12, 2009·Updated Oct 12, 2022

In Brief

A Phase 3 clinical trial evaluating lanreotide (Autogel formulation) for Non Functioning Entero-pancreatic Endocrine Tumour. Completed, enrolled 89 participants across 25 sites in 9 countries.

Detailed Summary

The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT00353496).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Functioning Entero-pancreatic Endocrine Tumour
CountriesBelgium, Czechia, France, Italy, Poland, Slovakia, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2009
Enrollment StartFeb 1, 2009
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 17.4 years ago

Interventions

lanreotide (Autogel formulation)drug

Autogel 120 mg